Sahee Park

发表

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

Sukjoong Oh, Y. Do, Joon Seong Park, 2014, Haematologica.

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation

Dong-Wook Kim, Soo-hyun Kim, S. Choi, 2012, International Journal of Hematology.

Dynamic change of T315I BCR‐ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors

Dong-Wook Kim, Soo-hyun Kim, Dongho Kim, 2009, Hematological oncology.

Analysis of Bcr‐Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P‐loop and T315I mutation is disease phase dependent

Dong-Wook Kim, Soo-hyun Kim, Se-Eun Jang, 2009, Hematological oncology.

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy

Yoo-Jin Kim, Hyeoung-Joon Kim, Dong-Wook Kim, 2009, Leukemia & lymphoma.

Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.

Dong-Wook Kim, H. Schran, Yanfeng Wang, 2011, British journal of clinical pharmacology.

AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth

Ita Novita Sari, T. Reya, H. Kwon, 2020, Oncogene.

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.

B. Cho, Dong-Wook Kim, Soo-hyun Kim, 2009, Leukemia research.

Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial

Sukjoong Oh, Joon Seong Park, G. Lee, 2012 .

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.

Anna L. Brown, Paul P. S. Wang, D. Thomson, 2018, Blood.

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.

Dong-Wook Kim, T. Hughes, S. Branford, 2020, Blood.